New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
05:41 EDTBIIBBiogen, Eisai enter collaboration develop, commercialize Alzheimerís treatments
Eisai and Biogen Idec announced that they have entered into a collaboration to develop and commercialize two of Eisaiís clinical candidates for Alzheimerís disease, or AD, E2609 and BAN2401. The agreement also provides Eisai with an option to jointly develop and commercialize two of Biogen Idecís candidates for AD, the anti-amyloid beta antibody BIIB037 and an anti-tau monoclonal antibody. The collaboration initially will be centered on the co-development and co-commercialization of Eisaiís two candidates: E2609, a beta-site amyloid precursor protein cleaving enzyme, or BACE, inhibitor, and BAN2401, an anti-amyloid beta antibody. These candidates have the potential to reduce amyloid beta plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression. Biogen Idec will provide Eisai with an upfront payment and a fixed amount of development, approval and commercial milestone payments. The agreement also includes options for Eisai to receive an additional one-time payment from Biogen Idec related to joint development and commercialization activities in Japan.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 15, 2015
07:29 EDTBIIBOutlook for Biogen trials positive , says RBC Capital
Subscribe for More Information
January 14, 2015
07:05 EDTBIIBIsis Pharmaceuticals earns $7M from Biogen for advancing muscular atrophy study
Subscribe for More Information
January 13, 2015
13:09 EDTBIIBBiogen CEO says company has strengthened R&D, to stay active in M&A
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use